#USA #New York #AI Platform #ACTO Technologies #Lori Tierney

ACTO Welcomes Lori Tierney to Its Board of Directors

On May 9, 2025, ACTO, a trailblazer in AI-powered Intelligent Field Excellence (IFE) focusing on the life sciences sector, announced the strategic appointment of Lori Tierney to its Board of Directors. Lori brings with her an extensive background in the industry, carrying over two decades of experience in launching transformative therapies and leading high-performing teams. This move comes at a pivotal moment as ACTO aims to redefine customer engagement through AI innovations.

Tierney, who was previously at the helm of Johnson & Johnson Vision, has an impressive track record in global and regional leadership roles within J&J MedTech and Mentor Aesthetics Specialty Surgery. Her career also includes significant positions at AstraZeneca, Endo Pharmaceuticals, and Centocor, where she successfully managed teams in global strategy, inline marketing, and sales operations. This wealth of experience positions her perfectly to help ACTO in its mission to accelerate the AI-driven future for the life sciences industry.

The appointment of Tierney arrives as the life sciences sector faces increasing pressure to enhance both revenue growth and operational efficiency. The industry is undergoing profound changes in how it interacts with healthcare professionals, patients, and payers, and the integration of AI has emerged from a luxury to a necessity. In this context, Tierney’s insights into business strategy—from brand launches to building sales teams and improving market access—will be invaluable.

In her own words, Tierney stated: "The way our industry interacts with medical professionals, patients, and payers is experiencing a deep transformation. AI is not a luxury; it's essential. ACTO is uniquely positioned to lead this shift, and I’m honored to support its mission of empowering individuals and organizations that deliver critical medical insights to the world, advancing healthcare and improving patient outcomes."

ACTO's Intelligent Field Excellence platform equips life science companies with AI-driven tools that foster competence, confidence, and credibility among sales representatives during their interactions with healthcare providers. This technology also provides executives with real-time insights that enable smarter decision-making and continuous improvement of business operations.

"We are thrilled to welcome Lori to our board," said ACTO's CEO, Parth Khanna. "She brings industry voice, a wealth of experience, and a bold vision that will be instrumental in leading us into an AI-driven future in life sciences. Lori embodies the values and ambitions that define ACTO, and her leadership will help accelerate our AI development in the industry."

In summary, Lori Tierney’s appointment is seen as a cornerstone for ACTO as it continues to innovate and expand its impact in the realm of life sciences. Keeping pace with technological advancements while prioritizing patient care remains crucial, and ACTO is poised to be a reliable partner in intelligent field excellence. To learn more about ACTO, visit www.acto.com or follow them on LinkedIn for the latest updates and announcements.